Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
NCT03541720Phase 1Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18f-fluorodopamine in neuroblastoma and pheochromocytoma, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Adverse event rate at 2 days. Started Apr 2019; status: active, not recruiting.
02
Drugs
18f-fluorodopamine
03
Conditions
neuroblastomapheochromocytoma
Beyond the preview
Go deeper on NCT03541720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541720.